RT Journal Article SR Electronic T1 Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 1951 OP 1957 DO 10.21873/invivo.12462 VO 35 IS 4 A1 IOANNIS PAPAKONSTANTINOU A1 MARIA KOSMIDOU A1 KONSTANTINA PAPATHANASIOU A1 EPAMEINONDAS KOUMPIS A1 ELENI KAPSALI A1 HARALAMPOS MILIONIS A1 THEODOROS P. VASSILAKOPOULOS A1 ALEXANDRA PAPOUDOU-BAI A1 ELEFTHERIA HATZIMICHAEL YR 2021 UL http://iv.iiarjournals.org/content/35/4/1951.abstract AB Background: Hepatic dysfunction in patients with classical Hodgkin lymphoma (cHL) is of multifactorial aetiology. Prompt evaluation with laboratory tests and imaging methods is sufficient for diagnosis in most cases. Intrahepatic cholestasis and vanishing bile duct syndrome (VBDS) may complicate cHL as rare paraneoplastic phenomena. Liver biopsy provides crucial evidence of cholestasis, and ductopenia, if present, confirms the diagnosis of VBDS. Case Report: We report on a cHL patient that presented with jaundice and bulky mediastinal disease and unfold the therapeutic dilemmas we confronted. Marked hyperbilirubinemia was successfully reversed with brentuximab vedotin (BV) at a dose of 1.2 mg/kg and the patient was subsequently treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) at full doses, achieving complete metabolic response. A literature review of intrahepatic cholestasis in cHL is also presented based on currently available data with focus on treatment options and clinicopathologic associations. Conclusion: VBDS and intrahepatic cholestasis are rare and potentially fatal complications of cHL. Their prompt recognition and appropriate treatment can dramatically affect cHL patients’ outcome. BV, used at a reduced dose as a bridging therapy, should be considered as a high-priority treatment plan in these challenging cases.